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Nucleosome positioning and reorganization regulate
DNA site exposure in chromatin. Platinum anticancer
agents form DNA adducts that disrupt nuclear activ-
ities, triggering apoptosis. Mechanistic insight would
aid in the development of improved therapies to cir-
cumvent drug toxicity and resistance. We show that
platinum adducts formed by reaction of cisplatin or
oxaliplatin with the nucleosome core inhibit histone
octamer-DNA sliding but do not cause significant al-
teration of positioning. Thus, adduct formation rein-
forces positional preferences intrinsic to the DNA
sequence, which indicates that modulation of plati-
num drug site selectivity by histone octamer associ-
ation may relate to nucleosome-specific properties
of DNA. This sheds light on platinum drug-mediated
inhibition of chromatin remodeling in vivo and sug-
gests that adducts can shield their own repair and
interfere with genomic activities by directly altering
nucleosome dynamics.
INTRODUCTION
The primary pharmacological effect of platinum-based chemo-
therapeutic agents is mediated through formation of DNA le-
sions, which interfere with genomic activities, such as transcrip-
tion, and ultimately trigger apoptosis (Jung and Lippard, 2007).
Drug reaction occurs at the N7 nitrogen atoms of purine bases,
generating predominantly 1,2 intrastrand cross-links at GG and
AG dinucleotides and a minor fraction of GXG 1,3 intrastrand
and other DNA-platinum adducts. Despite their widespread ap-
plication in the treatment of specific cancers, the most success-
ful platinum drugs—cisplatin (cisPt, 1), oxaliplatin (oxPt, 2), and
carboplatin—elicit severe toxicity and resistance effects (Rabik
and Dolan, 2007; Kelland, 2007). The development of improved
agents or that of therapeutic tactics exploiting the synergy of
multiple drugs administered simultaneously is contingent upon
a detailed understanding of the mechanism of action of medici-
nal compounds within the cell.
An additional level of complexity in the activity of DNA-binding
agents arises from the packaging of DNA into chromatin (Korn-
berg and Lorch, 2007). The basic building block of this dynamic
assembly is the nucleosome core particle (NCP), in which 147Chemistry & Biology 15, 1023–base pairs (bp) of DNA are wrapped in one and two-thirds left-
handed superhelical turns around a histone protein octamer
(Richmond and Davey, 2003). Adjacent nucleosomes in vivo are
connected by typically 10–50 bp of linker DNA. Thus, approxi-
mately 83%of genomicDNA is associatedwith histone octamers
(Segal et al., 2006), making the nucleosome core an important
drug target. Nonetheless, comparatively little is known about
the influence of DNA-drug interaction on chromatin function.
The locations occupied by nucleosomes in vivo are strongly
influenced by DNA sequence, and the resulting chromatin archi-
tecture modulates genomic activities in a gene-specific and
state-dependent manner (Yuan et al., 2005; Segal et al., 2006;
Lee et al., 2007; Boyle et al., 2008; Schones et al., 2008). For
instance, genomic sequence elements promote nucleosome
depletion over a defined region of the promoter, which is flanked
by strongly positioned nucleosomes. This provides the basis for
regulation of transcription, which, like many genomic processes,
including replication and repair, relies on reorganization or tran-
sient alteration of nucleosomes to allow factor access to specific
DNA sites. Nucleosome displacement at promoters during
gene activation (Yuan et al., 2005; Lee et al., 2007; Schones
et al., 2008) involves the activity of ATP-dependent chromatin
remodeling factors (Li et al., 2007). Moreover, DNA lesion repair
can be modulated by nucleosome dynamics and facilitated by
remodeling activities (Thoma, 2005; Saha et al., 2006). There-
fore, an exogenous agent that perturbs the kinetic balance
governing nucleosome position and mobility is likely to affect
genomic function.
An earlier study investigated the effect of cisPt on hormone-
induced transcription from the mouse mammary tumor virus
promoter (Mymryk et al., 1995). Treatment of cells with cisPt
led to a substantial decrease in gene expression, accompanied
by corresponding reduction in chromatin remodeling and
transcription factor binding at the promoter. Although the mech-
anism of this drug-induced inhibition of chromatin remodeling is
not clear, studies have shown that cisPt adducts engineered into
naked DNA subsequently reconstituted into nucleosomes can
alter histone octamer positioning (Danford et al., 2005; Ober
and Lippard, 2008). This suggests that cisPt adduct formation
on linker DNA could influence the outcome of nucleosome reor-
ganization processes, which call for histone octamer movement
onto regions previously unoccupied by nucleosomes.
We have recently shown that histone octamer association
modulates the site selectivity of cisPt and oxPt (Wu et al.,
2008), which suggests that the effect of adducts on nucleosome
positioning may depend on whether the initial substrate is naked1028, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1023
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Platinum Drug Adducts Alter Nucleosome MobilityFigure 1. Distinct Translational Positioning and Histone Octamer Sliding in the NCP
(A) Five percent native PAGE analysis of DNA and NCP, 146b and 147. Heat treatment (D) promotes histone octamer repositioning to yield exclusively the faster
migrating centered form of NCP, in which histone-DNA contacts are maximal. Marker (m) consists of a 100 bp ladder.
(B) View of the NCP with the particle pseudo-twofold axis running vertically through the middle (DNA, colored; histone proteins, gray). The centered (bottom)
versus off-centered (top) forms of NCP differ in positioning by a single turn of the double helix.or nucleosomal DNA. Considering that most platinum drug
adducts appear to form and accumulate in nucleosome core
regions of the genome (Davey and Davey, 2008), we conducted
a study to assess the influence of such adduct formation on
nucleosome positioning and mobility.
RESULTS
NCP147 and NCP146b were assembled from recombinant Xen-
opus laevis histones and 147 bp or 146 bp fragments of differing
sequence based on human a-satellite DNA (Luger et al., 1999;
Davey et al., 2002). These constructs each yield two distinctly
positioned species upon reconstitution (Figure 1). The symmet-
rically aligned, centered form is thermodynamically favored
and differs in position by 10 bp relative to the off-centered
form (Luger et al., 1999). Thus, the two species share the same
rotational phase of DNA with respect to histone octamer and dif-
fer only in translational position. Incubation at elevated tempera-
ture promotes repositioning of the histone octamer to yield
purely centered NCP (see Figure 1).
Predominantly off-centered NCP was generated by conduct-
ing reconstitution at 4C. Samples in a buffer of 20 mM K-Caco-
dylate (pH 6.0) were treated with three different cisPt:NCP or
oxPt:NCP stoichiometry for 48 hr at 4C and subjected to heat
shifting to assess propensity for repositioning (Figure 2). Relative
to untreated samples, higher stoichiometry of drug treatment re-
sults in an increasing reduction in rate of histone octamer repo-
sitioning to the centered form. A similar degree of reduction in
mobility occurs at a roughly 10- to 20-fold higher stoichiometry
of oxPt treatment relative to cisPt.1024 Chemistry & Biology 15, 1023–1028, October 20, 2008 ª2008A much lower DNA reactivity of oxPt compared with cisPt has
been documented previously (Woynarowski et al., 1998). To ob-
tain a more in-depth understanding of the drug and DNA se-
quence dependency of the observed mobility reduction, we
used an atomic absorption spectrophotometer to measure plat-
inum content in NCP treated with cisPt or oxPt. The relative re-
activity of cisPt versus oxPt displays some variation with DNA
sequence (between NCP147 and NCP146b), but on average
oxPt yields a similar number of NCP adducts at a 19-fold higher
stoichiometry compared with cisPt at 4C (Figure 3). Removal of
histone proteins from NCP samples by extraction also allows
quantification of platinum in the DNA fraction alone. The histone
versus DNA distribution of platinum adducts displays slight DNA
sequence dependence, yet differs substantially between cisPt
and oxPt. On average, 73% of the cisPt adducts are associated
with the DNA, compared with only 59% of the oxPt adducts. The
remaining platinum fraction corresponds mostly to histone me-
thionine adducts, of which H3 Met120 and H4 Met84 are likely
to be the primary sites of attack (Wu et al., 2008).
The large difference in the observed reactivity between cisPt
and oxPt at 4C indicates a similar influence of the two adduct
types on nucleosome mobility. An effect is apparent from the
lowest cisPt and oxPt stoichiometry tested, indicating that as lit-
tle as one platinum adduct per nucleosome can influence mobil-
ity (see Figure 2). In addition, for approximately the same average
number of NCP- or DNA-platinum adducts, the two drug types
elicit a similar degree of mobility reduction for NCP146b. How-
ever, the effect is significantly stronger with fewer oxPt com-
pared with cisPt adducts for NCP147, which thus reveals both
DNA sequence and drug dependence for this phenomenon.Elsevier Ltd All rights reserved
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Platinum Drug Adducts Alter Nucleosome MobilityFigure 2. Native PAGE Analysis of Platinum Drug-Treated NCP
Reveals the Influence of Adducts on Nucleosome Positioning and
Mobility
(A and B) NCP was treated with different cisPt (A) or oxPt (B) stoichiometry
(drug:NCP) and subjected to thermal incubation for 20 min at 37C
(NCP147) or 1 hr at 50C (NCP146b; –/D, before/after heat treatment). Gels
were stained with ethidium bromide (dark background) and Coomassie blue
(light background). The upper and lower bands are off-centered and centered
NCP, respectively. Average number of platinum adducts on the DNAor NCP (in
parentheses) was determined by atomic absorption spectrophotometry (see
text and Figure 3A for details).Chemistry & Biology 15, 1023–Having established that a substantial fraction of the platinum
adducts from cisPt or oxPt treatment of NCP are associated
with histone proteins raised the possibility that the observed in-
hibition of nucleosome sliding arises from histone-platinum-DNA
cross-links. If formed, such cross-links could effectively ‘‘ce-
ment’’ the histone octamer in its initial position. However, reduc-
ing agent-free SDS-PAGE analysis of drug-treated NCP indi-
cates the absence of significant protein-DNA cross-linking (see
Figure S1 available online). Moreover, subjection of cisPt- or
oxPt-treated NCP147 to extended heat incubation results in es-
sentially complete repositioning to the centered form (Figure 4).
For NCP146b, which requiresmuch higher temperature for repo-
sitioning, the core particle begins to degrade or dissociate after
extended heat treatment. Nonetheless, long-term incubation,
short of substantial dissociation, yields primarily the centered
form of drug-treated NCP146b. Therefore, platinum adducts re-
siding on DNA or histone give rise to an increased energy barrier
toward histone octamer-DNA sliding.
Electrophoretic mobility shift assay is highly sensitive to
changes in DNA conformation, such that even differences in ori-
entation of the protruding DNA arm of off-centered NCP can be
resolved (Luger et al., 1999). In the present study, we observe no
significant degree of alteration in electrophoretic mobility of ei-
ther the off-centered or centered forms of drug-treated NCP rel-
ative to native samples (Figure 2). This encompasses both before
and after heat treatment, aswell as the extended thermal incuba-
tion trials, which yield predominantly centered form having elec-
trophoretic migration rate equivalent to native NCP (Figure 4).
Thus, although substantial conformational changes are apparent
for the DNA extracted from drug-treated NCP (Figure 3B), plati-
num adduct formation in the nucleosome core does not result in
any gross structural alterations, even when the adduct number
exceeds, on average, eight per NCP. Furthermore, previous in-
vestigations on cisPt-derivatized DNA reconstituted into nucleo-
somes have indicated that adducts can profoundly alter histone
octamer positional preference, causing inversion of rotational
phase by 5 bp and up to 20 bp changes in translational setting
(Danford et al., 2005; Ober and Lippard, 2008). The systematic
absence of differences in gel mobility arising from adduct forma-
tion observed here indicates the lack of pronounced change in
positional preference upon platinum drug reaction with nucleo-
somes.
DISCUSSION
The association of minor groove binding polyamides has been
observed to suppress histone octamer-DNA sliding in the nucle-
osome (Suto et al., 2003). In addition, substitution of rigid DNA
sequence elements into the nucleosome core, such as long
poly(A) tracts, also results in a decrease in nucleosome mobility
(Bao et al., 2006). Our findings on the effect of platinum adducts
suggests that DNA cross-linking underlies the reduction in nucle-
osome mobility. Although platinum adducts on methionine resi-
dues could potentially influence nucleosome dynamics, the mo-
bility reduction apparently stems from a decrease in DNA
(C) Band densitometry analysis of ethidium bromide-stained gels in (A) and (B)
showing extent of repositioning (1  [percent off-centered NCP after heat
treatment/percent off-centered NCP before heat treatment]) relative to num-
ber of DNA-platinum adducts.1028, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1025
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Platinum Drug Adducts Alter Nucleosome Mobilityflexibility conferred by cross-linking. In view of the capacity of the
nucleosome core to accommodate platinum lesions without
large structural changes (Wu et al., 2008), adduct formation
may permit native-like histone-DNA interactions while reducing
DNAmobility through suppression of twisting and looping distor-
tions.
UV-induced pyrimidine-pyrimidine cross-links formed on na-
ked DNA give rise to alterations in positioning when reconsti-
tuted into nucleosomes, such that the lesions are preferentially
oriented away from the histone octamer (Thoma, 2005). Con-
versely, UV cross-link formation in the nucleosome does not re-
sult in positional change; rather, lesions are preferentially gener-
ated at locations facing away from the histone octamer. Thus,
histone octamer association modulates lesion formation by sys-
tematically altering the energetics of cross-link formation, which
consequently complements the positioning preference of the
DNA. This may be a phenomenon common to many types of le-
Figure 3. Quantification of Platinum Ad-
ducts in the NCP
(A) A Hitachi Z-2000 polarized Zeeman atomic ab-
sorption spectrophotometer was used to measure
platinum content of cisPt- or oxPt-treated NCP.
For determining average number of adducts asso-
ciated with the DNA (dashed lines), histone pro-
teins were removed by incubating NCP with 2M
NaCl at 55C for 1 hr, followed by phenol-chloro-
form extraction and ethanol precipitation and re-
suspension of the DNA. Values correspond to
the average of three measurements, with an over-
all root-mean-square deviation of 7%.
(B) Five percent native PAGE analysis of DNA ex-
tracted from cisPt- or oxPt-treated NCP147 and
NCP146b. Drug stoichiometry and average num-
ber of platinum adducts per DNA molecule are
given.
sion formation in the nucleosome, which
give rise to conformational distortions in
the DNA. We find that an analogous sce-
nario occurs with platinating compounds,
in that cross-links formed on naked DNA
can change histone octamer positioning
(Danford et al., 2005; Ober and Lippard,
2008), whereas lesion formation in the nu-
cleosome core does not alter positioning.
In fact, by inhibiting histone octamer slid-
ing, platinum adducts are reinforcing in-
trinsic positional preferences.
A modulation of platinum adduct for-
mation by histone octamer association
(Wu et al., 2008), which strengthens but
does not alter nucleosome positioning
suggests the capacity of the nucleo-
some to permit cross-link formation
where it can most readily accommodate
histone-imposed conformational re-
straints. Previous work has shown that
1,3 GTG or 1,2 GG cisPt cross-links
formed on naked DNA assume positions in the nucleosome
where the major groove faces inward, toward the histone oc-
tamer (Ober and Lippard, 2007, 2008). Consistent with this,
we have observed one of the primary sites of cisPt attack on
naked DNA, corresponding to a location where the major
groove faces away from histone octamer, to be substantially
protected in the NCP (Wu et al., 2008). At several other loca-
tions, adduct formation appears enhanced relative to naked
DNA. These preferred positions of attack in the nucleosome
may be those that best accommodate DNA conformational re-
straints and have the potential to strengthen positional cues.
SIGNIFICANCE
The present findings shed light on the physiological conse-
quences of platinum drug reaction with chromatin, indicat-
ing that adduct formation may preserve and reinforce1026 Chemistry & Biology 15, 1023–1028, October 20, 2008 ª2008 Elsevier Ltd All rights reserved
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Platinum Drug Adducts Alter Nucleosome MobilityFigure 4. NativePAGEAnalysisofPlatinumDrug-TreatedNCPShow-
ing the Influence of Adducts on Nucleosome Positional Preference
(A and B) Samples were treated with 5:1 cisPt:NCP (A) or 50:1 oxPt:NCP
(B) stoichiometry and subjected to thermal incubation at 37C (NCP147) or
50C (NCP146b) for up to 6 hr (–, before heat treatment). The first time point
for NCP146b is 30 min, as opposed to 10 min for NCP147, due to the lower in-
trinsic mobility of the former. Gels were stained with ethidium bromide (dark
background) and Coomassie blue (light background).
(C) Band densitometry analysis of ethidium bromide-stained gels in (A) and (B)
showingpositioning as a function of incubation time. Note that the upward smear-
ing of centered NCP bands resulting from core particle disassociation upon ex-
tended thermal incubation gives rise to an overestimation of the off-centered
NCP fraction.Chemistry & Biology 15, 1023–nucleosome positioning. The reduction in nucleosome mo-
bility conferred by cisPt or oxPt adducts may contribute to
the pharmacological activity of this class of agent, and sug-
gests that the inhibition of chromatin remodeling found
in vivo for cisPt treatment (Mymryk et al., 1995) may arise
in part via direct alteration of nucleosome dynamics.
DNA-adduct levels in cancer patients treated with plati-
num drugs, up to 1 per 4200 bp for cisPt regimens, are lower
than those observed for in vitro studies (Kloft et al., 1999;
Pieck et al., 2008). However, the distribution of cisPt and
oxPt adducts in cellular DNA is markedly nonuniform (Woy-
narowski et al., 1998; Davies et al., 2000), and recent work
suggests that adducts may accumulate disproportionately
in the nucleosome core regions of the genome (Wu et al.,
2008; Davey and Davey, 2008). Therefore, the observed
DNA sequence and drug dependence of nucleosome mobil-
ity modulation indicates that specific elements in the ge-
nome may be differentially affected. Furthermore, because
histone octamer association inhibits the repair of platinum
adducts (Wang et al., 2003), it appears that adductsmay con-
tribute to shielding their own repair by hindering dynamic
site exposure. As such, the discovery of agents that could
markedly suppress mobility of nucleosomes at vulnerable
genomic elements may hold therapeutic promise by ham-
pering DNA repair processes.
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